CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,719,151 | +117.1% | 461,303 | +31.5% | 0.00% | +100.0% |
| Q2 2023 | $6,320,299 | +13.9% | 350,738 | +1.5% | 0.00% | 0.0% |
| Q1 2023 | $5,549,806 | -11.6% | 345,567 | +0.7% | 0.00% | 0.0% |
| Q4 2022 | $6,277,907 | -4.9% | 343,055 | +2.0% | 0.00% | 0.0% |
| Q3 2022 | $6,603,000 | +6.7% | 336,190 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $6,186,000 | -5.5% | 331,671 | +11.3% | 0.00% | 0.0% |
| Q1 2022 | $6,544,000 | -20.5% | 298,125 | +2.9% | 0.00% | 0.0% |
| Q4 2021 | $8,232,000 | +75.1% | 289,735 | +29.8% | 0.00% | 0.0% |
| Q3 2021 | $4,700,000 | +27.2% | 223,247 | +13.9% | 0.00% | +100.0% |
| Q2 2021 | $3,694,000 | +60.3% | 195,921 | +30.0% | 0.00% | 0.0% |
| Q1 2021 | $2,304,000 | +8.3% | 150,752 | +0.0% | 0.00% | 0.0% |
| Q4 2020 | $2,127,000 | -7.6% | 150,723 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $2,302,000 | -2.7% | 146,871 | +8.8% | 0.00% | 0.0% |
| Q2 2020 | $2,365,000 | +204.8% | 134,974 | +156.0% | 0.00% | – |
| Q1 2020 | $776,000 | -41.6% | 52,722 | -0.4% | 0.00% | -100.0% |
| Q4 2019 | $1,329,000 | +73.0% | 52,947 | +3.8% | 0.00% | – |
| Q3 2019 | $768,000 | -33.4% | 51,003 | +10.5% | 0.00% | -100.0% |
| Q2 2019 | $1,154,000 | +26.0% | 46,146 | +14.7% | 0.00% | 0.0% |
| Q1 2019 | $916,000 | -9.8% | 40,217 | +18.7% | 0.00% | 0.0% |
| Q4 2018 | $1,016,000 | -1.7% | 33,874 | -6.1% | 0.00% | 0.0% |
| Q3 2018 | $1,034,000 | – | 36,066 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |